Advertisement

Drugs

, Volume 28, Issue 2, pp 93–98 | Cite as

Current Status of Chemotherapy of Breast Cancer

  • Alan Coates
Leading Article
  • 6 Downloads

Keywords

Breast Cancer Metastatic Breast Cancer Combination Chemotherapy Advanced Breast Cancer Southwest Oncology Group Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baum, M.; Dossett, J.A.; Patterson, J.S.; Smiddy, F.G.; Wilson, A.; Richards, D.; Brinkley, D.M.; McPherson, K.; Rubens, R.D.; Stoll, B.A.; Lea, J.C. and Ellis, S.H.: Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.Lancet 2: 450 (1983).PubMedCrossRefGoogle Scholar
  2. Bitran, J.D.; Desser, R.K.; Shapiro, CM.; Michel, A.; Kozloff, M.F.; Billings, A.A. and Recent, W.: Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51: 381–384 (1983).PubMedCrossRefGoogle Scholar
  3. Bonadonna, G. and Valagussa, P.: Chemotherapy of breast cancer: Current views and results. International Journal of Radiation Oncology, Biology, Physics 9: 279–297 (1983).PubMedCrossRefGoogle Scholar
  4. Broder, L. and Tormey, D.C.: Combination chemotherapy of carcinoma of the breast: A review. Cancer Treatment Reviews 1: 183–203 (1974).CrossRefGoogle Scholar
  5. Canellos, G.P.; Pocock, S.J.; Taylor, S.G.; Sears, M.E.; Klaasen, D.J. and Band, P.R.: Combination chemotherapy for metastatic breast cancer. Prospective comparison of multiple drug therapy with 1-phenylalanine mustard. Cancer 38: 1882–1886 (1976).PubMedCrossRefGoogle Scholar
  6. Carbone, P.P., Bauer, M.; Band, P. and Tormey, D.: Chemotherapy of disseminated breast cancer: Current status and prospects. Cancer 39: 2916–2922 (1977).PubMedCrossRefGoogle Scholar
  7. Carbone, P.P. and Davis, T.E.: Medical treatment for advanced breast cancer. Seminars in Oncology 5: 417–427 (1978).PubMedGoogle Scholar
  8. Carter, S.K.: Integration of chemotherapy into combined modality treatment of solid tumors. VII. Adenocarcinoma of the breast. Cancer Treatment Reviews 3: 141–174 (1976).PubMedCrossRefGoogle Scholar
  9. Cavalli, F.; Beer, M.; Martz, G.; Jungi, W.F.; Alberto, P.; Obrecht, J.P.; Mermillod, B. and Brunner, K.W.: Concurrent or sequential use of cyto-toxic chemotherapy and hormone-treatment in advanced breast-cancer. Report of the Swiss Group for Clinical Cancer Research. British Medical Journal 286: 5–8 (1983).PubMedCrossRefGoogle Scholar
  10. Chlebowski, R.T.; Irwin, L.E.; Pugh, R.P.; Sadoff, L.; Hestorff, R.; Weiner, J.M. and Bateman, J.R.: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Research 39: 4503–4506 (1979).PubMedGoogle Scholar
  11. Chlebowski, R.T.; Weiner, J.M.; Luce, J.; Hestorff, R.; Lang, J.E.; Reynolds, R.; Godfrey, T.; Ryden, V.M.J. and Bateman, J.R.: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone for high-risk breast cancer. A Western Cancer Study Group project. Cancer Research 41: 4399–4403 (1981).PubMedGoogle Scholar
  12. Coates, A.S.; Abraham, S.; Kaye, S.B.; Sowerbutts, T.; Frewin, C; Fox, R.M. and Tattersall, M.H.N.: On the receiving end. Patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology 19: 203–208 (1983a).CrossRefGoogle Scholar
  13. Coates, A.S.; Fisher Dillenbeck, C; McNeil, D.R.; Kaye, S.B.; Sims, K.; Fox, R.M.; Woods, R.L.; Milton, G.W.; Solomon, J. and Tattersall, M.H.N.: On the receiving end. II. Linear analogue self assessment (LASA) in evaluation of the quality of life of cancer patients receiving therapy. European Journal of Cancer and Clinical Oncology 19: 1633–1638 (1983b).CrossRefGoogle Scholar
  14. Cooper, R.: Combination chemotherapy in hormone resistant breast cancer (abstract). Proceedings of the American Association for Cancer Research 10: 15 (1969).Google Scholar
  15. De Lena, M.; Zucali, R.; Viganotti, G.; Valagussa, P. and Bonadonna, G.: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemotherapy and Pharmacology 1: 53–59 (1978).PubMedCrossRefGoogle Scholar
  16. Fisher, B.: Redmond, C; Brown, A.; Wickerham, D.L.; Wolmark, M.; Allegra, J.; Escher, G.: Lippman, M; Savlov, E.; WittlifT, J.; Fisher, E.R.; Plotkin, D.; Bowman, D.; Wolter, J.; Bornstein. R.; Desser, R. and Frelick, R.: Influence of tumor estrogen and progesterone-receptor levels on the response to tamoxifen and chemotherapy in primary breast-cancer. Journal of Clinical Oncology. 1: 227–241 (1983).PubMedGoogle Scholar
  17. Fisher, B.; Redmond, C; Wolmark, N. and Wieand, H.S.: Disease-free survival at intervals during and following completion of adjuvant chemotherapy: The NSABP experience from three breast cancer protocols. Cancer 48: 1273–1280 (1981).PubMedCrossRefGoogle Scholar
  18. Forbes. J.F.: Breast cancer: Advanced disease. Clinics in Oncology 1: 149–175 (1982).Google Scholar
  19. Glucksberg, H.; Rivkin, S.E.; Rasmusseen, S.; Tranum, B.; Gadel-Malwa, N.; Costanzi, J.; Hoogstraten, B.; Athens, J.; Maloney. T.; McCracken, J. and Vaughn, C: Combination chemotherapy (CMFVP) versus 1-phenylalanine mustard (1-PAM) for operable breast cancer with positive axillary nodes. A Southwest Oncology Group study. Cancer 50: 423–434 (1982).PubMedCrossRefGoogle Scholar
  20. Goldhirsch, A.: Toxic effects of early adjuvant chemotherapy for breast-cancer. Lancet 2: 542–544 (1983).Google Scholar
  21. Goldie, J.H. and Coldman, A.J.: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports 63: 1727–1733 (1979).PubMedGoogle Scholar
  22. Greenspan, E.: Response of advanced breast cancer to the combination of the antimetabolite, methotrexate, and the alkylating agent thio-TEPA. Journal of the Mount Sinai Hospital, New York 30: 246–267 (1963).PubMedGoogle Scholar
  23. Greenspan, E.: Combination cytotoxic chemotherapy in advanced disseminated breast cancer. Journal of the Mount Sinai Hospital, New York 33: 1–27 (1966).PubMedGoogle Scholar
  24. Haybittle, J.L.: What is cure in cancer? in Stoll (Ed.) Cancer Treatment: End Point Evaluation, pp.3–21 (John Wiley and Sons, Chichester 1983).Google Scholar
  25. Hoogstraten, B.: George, S.L.; Samal, B.; Rivkin, S.E.; Costanzi, J.J.; Bonnet, J.D.; Thigpen, T. and Braine, H.: Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer 38: 13–20 (1976).PubMedCrossRefGoogle Scholar
  26. Irwin, L.E.: Chlebowski, R.T.; Weiner, J.M.; Reynolds, R.; Pugh, R.P.; Ryden, V.M. and Bateman, J.R.: Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: A Western Cancer Study Group trial. Cancer Treatment Reports 64: 981–984 (1980).PubMedGoogle Scholar
  27. Langlands, A.O.; Pocock, S.J.; Kerr, G.R. and Gore, S.M.: Longterm survival of patients with breast cancer: A study of the curability of the disease. British Medical Journal 2: 1247–1251 (1979).PubMedCrossRefGoogle Scholar
  28. McBride, CM.; Brown, B.W.; Thompson, J.R.; Westbrook, K.C. and Milne, C.A.: Can patients with breast cancer be cured of their disease? Cancer 51: 938–945 (1983).PubMedCrossRefGoogle Scholar
  29. Meakin, J.W.; Allt, W.E.C; Beale, F.A.; Brown, T.C.; Bush, R.S.; Clark, R.M.; Fitzpatrick, P.J.; Hawkins, N.V.; Jenkin, R.D.T.; Pringle, J.F., Reid, J.G.; Rider, W.D.; Hayward, J.L. and Bulbrook. R.D.: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Canadian Medical Association Journal 120: 1221–1229 (1979).PubMedGoogle Scholar
  30. Miller, A.B.; Hoogstraten, B.; Staquet, M. and Winkler, A.: Reporting results of cancer treatment. Cancer 47: 207–214 (1981).PubMedCrossRefGoogle Scholar
  31. Muss. H.B.; White, D.R.; Richards, F.; Cooper, M.R.; Stuart, J.J.; Jackson, D.F.; Rhyne, L. and Spurr, C.L.: Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141–2148 (1978).PubMedCrossRefGoogle Scholar
  32. Nissen-Meyer, R.; Kjellgren, K.; Malmio, K.; Mansson, B. and Norin, T.: Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088–2098 (1978).PubMedCrossRefGoogle Scholar
  33. Powles. T.J.; Smith, I.E.; Ford, H.T.; Coombes, R.C.; Jones, J.M. and Gazet, J.C.: Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1: 580–582 (1980).PubMedCrossRefGoogle Scholar
  34. Priestman, T.J. and Baum, M.: Evaluation of the quality of life in patients receiving treatment for advanced breast cancer. Lancet 1: 899–901 (1976).PubMedCrossRefGoogle Scholar
  35. Rozencweig, M., Heuson, J.C.; von Hoff, D.D.; Mattheim, W.H.; Davis. H.L. and Muggia, F.M.: Breast cancer; in Staquet (Ed.) Randomized Trials in Cancer: A Critical Review by Sites, pp. 231–272 (Raven Press, New York 1978).Google Scholar
  36. Smalley, R.V.; Murphy, S.; Huguley, CM. and Bartolucci, A.A. (for the Southeast Cancer Study Group): Combination versus sequential five drug chemotherapy in metastatic carcinoma of the breast. Cancer Research 36: 3911–3916 (1976).PubMedGoogle Scholar
  37. Spitzer, W.O.; Dobson, A.L.; Hall, J.; Chesterman, E.; Levi, J.A.; Shepherd, R.; Battista, N. and Catchlove, B.R.: Measuring the quality of life of cancer patients. A concise QL index for use by physicians. Journal of Chronic Diseases 34: 585–597 (1981).PubMedCrossRefGoogle Scholar
  38. Stuart-Harris, R.C.; Bozek, T.; Pavlidis, N.A. and Smith, I.E.: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemotherapy and Pharmacology 12: 1–4 (1984).PubMedCrossRefGoogle Scholar
  39. Tormey, D.; Gelman, R. and Falkson, G.: Prospective evaluation of rotating chemotherapy in advanced breast-cancer — an Eastern Cooperative Oncology Group trial. American Journal of Clinical Oncology - Cancer Clinical Trials 6: 3–17 (1983a).Google Scholar
  40. Tormey, D.C; Gelman, R.; Band, P.R.; Sears, M.; Rosenthal, S.N.; DeWys, W.; Perlia, C and Rice, M.A.: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group trial. Cancer 50: 1235–1244 (1982).PubMedCrossRefGoogle Scholar
  41. Tormey, D.C; Weinberg, V.E.; Holland, J.F.; Weiss, R.B.; Glidewell, O.J.; PerlofT, M.; Falkson, G.; Falkson, H.C.; Henry, P.H.; Leone, LA.; Rafla, S.; Ginsberg, S.J.; Silver, R.T.; Blom, J.; Carey, R.W.; Schein, P.S. and Lesnick, G.J.: A randomized trial of 5 and 3 drug chemotherapy and chemo-immunotherapy in women with operable node positive breast-cancer. Journal of Clinical Oncology 1: 138–145 (1983b).PubMedGoogle Scholar
  42. Tranum, B.L.; McDonald, B.; Thigpen, T.; Vaughn, C; Wilson, H.; Maloney, T.; Costanzi, J.; Bickers, J.; Gad-el-Mawli, N.; Palmer, R.; Hoogstraten, B.; Heilburn, L. and Rasmusen, S.: Adriamycin combinations in advanced breast cancer. Cancer 49: 835–839 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1984

Authors and Affiliations

  • Alan Coates
    • 1
  1. 1.Ludwig Institute for Cancer Research (Sydney Branch)University of SydneySydneyAustralia

Personalised recommendations